TCT Takes The Stage; Sapien Set To Play The Lead

Article preview from "The Gray Sheet" - September 20, 2010

U.S. approval of the first transcatheter aortic valve replacement may be at least a year away, but the buzz surrounding the technology could go into overdrive at this week's Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.

TCT Takes The Stage; Sapien Set To Play The Lead

Article preview from "The Gray Sheet" - September 20, 2010

U.S. approval of the first transcatheter aortic valve replacement may be at least a year away, but the buzz surrounding the technology could go into overdrive at this week's Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.

And meeting organizers are doing little to discourage that.

"We are calling this the initiation of the era of valve interventions," said Gregg Stone, who directs the conference along with Martin Leon. Both are interventional cardiologists at Columbia University. Leon is the inventor of the Sapien transcatheter valve and the lead investigator of Edwards Lifesciences' pivotal PARTNER trial for the device, which will headline the influential meeting.

By David Filmore


To  purchase this article online or get it FREE when you subscribe to "The Gray Sheet".


Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512